ES2661601T3 - Anticuerpo humanizado antioligómero de amiloide-beta - Google Patents
Anticuerpo humanizado antioligómero de amiloide-beta Download PDFInfo
- Publication number
- ES2661601T3 ES2661601T3 ES10806566.5T ES10806566T ES2661601T3 ES 2661601 T3 ES2661601 T3 ES 2661601T3 ES 10806566 T ES10806566 T ES 10806566T ES 2661601 T3 ES2661601 T3 ES 2661601T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- amino acid
- humanized
- oligomer
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23203809P | 2009-08-07 | 2009-08-07 | |
| US232038P | 2009-08-07 | ||
| PCT/JP2010/063430 WO2011016567A1 (ja) | 2009-08-07 | 2010-08-06 | 抗アミロイドβオリゴマーヒト化抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2661601T3 true ES2661601T3 (es) | 2018-04-02 |
Family
ID=43544461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10806566.5T Active ES2661601T3 (es) | 2009-08-07 | 2010-08-06 | Anticuerpo humanizado antioligómero de amiloide-beta |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8333967B2 (pl) |
| EP (1) | EP2463368B1 (pl) |
| JP (1) | JP5051806B2 (pl) |
| KR (1) | KR101787118B1 (pl) |
| CN (1) | CN102597234B (pl) |
| AU (1) | AU2010279892B8 (pl) |
| BR (1) | BR112012002819B1 (pl) |
| CA (1) | CA2769464C (pl) |
| DK (1) | DK2463368T3 (pl) |
| ES (1) | ES2661601T3 (pl) |
| HU (1) | HUE036392T2 (pl) |
| MX (1) | MX2012001708A (pl) |
| PL (1) | PL2463368T3 (pl) |
| PT (1) | PT2463368T (pl) |
| SG (1) | SG177679A1 (pl) |
| WO (1) | WO2011016567A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6683602B2 (ja) * | 2014-04-16 | 2020-04-22 | 協和キリン株式会社 | ヒトｃｓｆの毒性を測定する方法 |
| EP3404040B1 (en) * | 2016-01-12 | 2022-03-02 | National University Corporation Chiba University | Anti-myl9 antibody |
| CN107118260B (zh) * | 2017-05-12 | 2020-10-16 | 中国科学院过程工程研究所 | 一种多肽及其组成的疫苗和应用 |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| US12016885B2 (en) * | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CA3185040A1 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN117586388A (zh) * | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 改进的β淀粉样蛋白寡聚体特异性结合抗体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| US6018032A (en) | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US20050059591A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| NZ579543A (en) * | 2004-07-09 | 2011-07-29 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
| JP3806883B2 (ja) | 2004-09-28 | 2006-08-09 | ダイキン工業株式会社 | 空気調和装置 |
| BRPI0516962A (pt) | 2004-10-25 | 2008-09-30 | Univ Northwestern | anticorpo isolado, ou fragmento do mesmo, composição farmacêutica, métodos para prevenir a ligação de ligantes difundìveis derivados de abeta a um neurÈnio, para inibir a constituição de ligantes difundìveis, para bloquear a fosforilação de proteìna, para tratar profilaticamente ou terapeuticamente uma doença, para identificar um agente terapêutico, para detectar ligantes difundìveis, e para diagnosticar uma doença, e, kit para detectar ligantes difundìveis |
| CN101137394A (zh) * | 2004-10-25 | 2008-03-05 | 默克制药公司 | 抗addl抗体及其应用 |
| WO2006075668A1 (ja) | 2005-01-12 | 2006-07-20 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG2およびIgG3抗体 |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| EP2210901A4 (en) * | 2007-10-19 | 2012-04-25 | Immunas Pharma Inc | FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE |
| PT2246427T (pt) * | 2008-02-08 | 2017-03-03 | Immunas Pharma Inc | Anticorpos capazes de se ligar especificamente a oligómeros beta amilóides e a sua utilização |
| TWI629483B (zh) * | 2010-06-11 | 2018-07-11 | 協和醱酵麒麟有限公司 | anti-TIM-3 antibody |
-
2010
- 2010-08-06 CA CA2769464A patent/CA2769464C/en active Active
- 2010-08-06 WO PCT/JP2010/063430 patent/WO2011016567A1/ja not_active Ceased
- 2010-08-06 CN CN201080035051.8A patent/CN102597234B/zh active Active
- 2010-08-06 BR BR112012002819-7A patent/BR112012002819B1/pt active IP Right Grant
- 2010-08-06 KR KR1020127003173A patent/KR101787118B1/ko active Active
- 2010-08-06 PL PL10806566T patent/PL2463368T3/pl unknown
- 2010-08-06 ES ES10806566.5T patent/ES2661601T3/es active Active
- 2010-08-06 SG SG2012003208A patent/SG177679A1/en unknown
- 2010-08-06 JP JP2011525961A patent/JP5051806B2/ja active Active
- 2010-08-06 MX MX2012001708A patent/MX2012001708A/es active IP Right Grant
- 2010-08-06 PT PT108065665T patent/PT2463368T/pt unknown
- 2010-08-06 AU AU2010279892A patent/AU2010279892B8/en active Active
- 2010-08-06 HU HUE10806566A patent/HUE036392T2/hu unknown
- 2010-08-06 DK DK10806566.5T patent/DK2463368T3/en active
- 2010-08-06 EP EP10806566.5A patent/EP2463368B1/en active Active
- 2010-08-09 US US12/852,548 patent/US8333967B2/en active Active
-
2012
- 2012-11-15 US US13/678,214 patent/US9181332B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR101787118B1 (ko) | 2017-10-18 |
| SG177679A1 (en) | 2012-02-28 |
| US20130095526A1 (en) | 2013-04-18 |
| PT2463368T (pt) | 2018-02-08 |
| JPWO2011016567A1 (ja) | 2013-01-17 |
| CA2769464C (en) | 2017-11-21 |
| US8333967B2 (en) | 2012-12-18 |
| CN102597234A (zh) | 2012-07-18 |
| MX2012001708A (es) | 2012-05-22 |
| HUE036392T2 (hu) | 2018-07-30 |
| DK2463368T3 (en) | 2018-01-22 |
| EP2463368A1 (en) | 2012-06-13 |
| EP2463368A9 (en) | 2012-11-28 |
| RU2012108610A (ru) | 2013-09-20 |
| BR112012002819B1 (pt) | 2022-11-22 |
| AU2010279892A8 (en) | 2014-09-25 |
| US20120009179A1 (en) | 2012-01-12 |
| CA2769464A1 (en) | 2011-02-10 |
| WO2011016567A1 (ja) | 2011-02-10 |
| EP2463368B1 (en) | 2018-01-10 |
| JP5051806B2 (ja) | 2012-10-17 |
| CN102597234B (zh) | 2014-10-29 |
| AU2010279892B8 (en) | 2014-09-25 |
| EP2463368A4 (en) | 2013-09-18 |
| AU2010279892B2 (en) | 2014-05-22 |
| US9181332B2 (en) | 2015-11-10 |
| AU2010279892A1 (en) | 2012-02-09 |
| BR112012002819A2 (pt) | 2017-07-11 |
| KR20120038474A (ko) | 2012-04-23 |
| PL2463368T3 (pl) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2661601T3 (es) | Anticuerpo humanizado antioligómero de amiloide-beta | |
| US8303954B2 (en) | Anti-Aβ oligomer humanized antibody | |
| RU2760875C1 (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения | |
| ES2887602T3 (es) | Anticuerpos anti-CD40 humanizados y usos de los mismos | |
| KR101629365B1 (ko) | 항원 결합성 단백질 | |
| ES2717908T3 (es) | Anticuerpos S100A4 y usos terapéuticos de los mismos | |
| WO2016073853A1 (en) | Anti-pro/latent-myostatin antibodies and uses thereof | |
| TW201716436A (zh) | 特異性針對過度磷酸化τ蛋白之抗體及其使用方法 | |
| CN116249717A (zh) | 识别分拣蛋白的抗体 | |
| TW202304974A (zh) | 抗tau抗體及其用途 | |
| AU2023225020A1 (en) | Methods of use of anti-trem2 antibodies | |
| RU2575095C2 (ru) | Гуманизированное антитело против олигомера бета-амилоида | |
| HK1170535A (en) | Humanized anti-amyloid-b oligomer antibody | |
| HK1170535B (en) | Humanized anti-amyloid-b oligomer antibody | |
| JP2025531392A (ja) | 抗ｃｃｒ８モノクローナル抗体およびそれらの治療的使用 | |
| HK40090814A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| HK40092141A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 |